Cases & Deals

AbbVie acquires Mavupharma

Clients AbbVie Inc.

Jones Day advised AbbVie Inc. in its acquisition of Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.